CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
Talazoparibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05141708
NCT05141708N/ACompleted
CompareCT.gov

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative Metastatic Breast Cancer and Germline BRCA1/2 Mutations: An Observational Study Using Flatiron Electronic Health Record (EHR) Database

Pfizer·observational·Posted Dec 2, 2021·Updated Feb 16, 2024

In Brief

An observational study evaluating Talazoparib for Metastatic Breast Cancer and Breast Neoplasms. Completed, enrolled 33 participants across 1 site.

Detailed Summary

This non-interventional retrospective study will describe real-world treatment patterns and clinical outcomes among adults with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations who initiated talazoparib as a first or later line of therapy. Patients will be identified from the Flatiron Electronic Health Record database.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer, Breast Neoplasms
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedDec 2, 2021
Enrollment StartDec 17, 2021
Primary CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.6 years ago

Interventions

Talazoparibdrug

Receipt of talazoparib as treatment for HER2-negative metastatic breast cancer with germline BRCA1/2 mutations anytime between January 1, 2018 and September 30, 2020